Spi Specialties Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 22.01%
- Profit Growth 27.36%
- Ebitda 43.26%
- Net Worth 27.03%
- Total Assets 29.94%
About Spi Specialties Pharma
Spi Specialties Pharma Private Limited (SSPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 05 December 2013 and has a history of 11 years and two months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sonya Dempster, Thopalli Ramamurthy, and Manjit Singh serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24100KA2013PTC072350
-
Company No.
072350
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Dec 2013
-
Date of AGM
05 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Spi Specialties Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sonya Dempster
|
Director | 22-Nov-2016 | Current |
Thopalli Ramamurthy
|
Director | 14-May-2018 | Current |
Manjit Singh
|
Director | 19-Nov-2015 | Current |
Financial Performance of Spi Specialties Pharma.
Spi Specialties Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 22.01% increase. The company also saw a substantial improvement in profitability, with a 27.36% increase in profit. The company's net worth Soared by an impressive increase of 27.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Spi Specialties Pharma?
In 2021, Spi Specialties Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Spi Specialties Pharma?
Spi Specialties Pharma has a workforce of 22 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Spi Specialties Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Spi Specialties Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
